Testosterone replacement therapy increase risks of CV events

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1764卷 / 1期
关键词：
D O I：
10.1007/s40278-019-65437-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：13 / 13
相关论文
共 50 条
  • [31] TESTOSTERONE REPLACEMENT THERAPY REDUCES CARDIOVASCULAR EVENTS IN MEN WITH CHRONIC KIDNEY DISEASE
    Chen, J.
    Boakye, Adjei E.
    McKee, A. M.
    Dhindsa, S. S.
    VALUE IN HEALTH, 2018, 21 : S104 - S105
  • [32] Cardiovascular risks with testosterone therapy
    Reactions Weekly, 2014, 1523 (1) : 2 - 2
  • [33] Advances in Testosterone Replacement Therapy
    Gooren, Louis J. G.
    ADVANCES IN THE MANAGEMENT OF TESTOSTERONE DEFICIENCY, 2009, 37 : 32 - 51
  • [34] WHICH TESTOSTERONE REPLACEMENT THERAPY
    CANTRILL, JA
    DEWIS, P
    LARGE, DM
    NEWMAN, M
    ANDERSON, DC
    CLINICAL ENDOCRINOLOGY, 1984, 21 (02) : 97 - 107
  • [35] PERSISTENCE WITH TESTOSTERONE REPLACEMENT THERAPY
    Camper, S. B.
    Puenpatom, R. A.
    Blanchette, C. M.
    Ma, L.
    VALUE IN HEALTH, 2014, 17 (03) : A163 - A163
  • [36] Andropause and testosterone replacement therapy
    de Castro, MPP
    CURRENT KNOWLEDGE IN REPRODUCTIVE MEDICINE, 2000, 1206 : 399 - 407
  • [37] Andrological testosterone replacement therapy
    Paasch, U.
    Glander, H. -J.
    Stolzenburg, J. -U.
    UROLOGE, 2009, 48 (01): : 79 - 86
  • [38] Testosterone replacement therapy - Introduction
    Wu, FCW
    TESTOSTERONE REPLACEMENT THERAPY, 1996, : 1 - 2
  • [39] Pharmacogenetics of testosterone replacement therapy
    Zitzmann, Michael
    PHARMACOGENOMICS, 2009, 10 (08) : 1341 - 1349
  • [40] Transurethral alprostadil: no increase in serious CV events
    Reactions Weekly, 1998, 730 (1) : 4 - 4
12345